China Greatwall Securities Co.Ltd(002939)
about
Zhejiangtailin Bioengineering Co.Ltd(300813) the gem issues convertible corporate bonds to unspecified objects
Issuance recommendation
Sponsor (lead underwriter)
(floors 10-19, South Tower, energy building, No. 2026, Jintian Road, Futian street, Futian District, Shenzhen)
statement
China Greatwall Securities Co.Ltd(002939) (hereinafter referred to as ” China Greatwall Securities Co.Ltd(002939) ” or “the sponsor”) accepts the entrustment of Zhejiangtailin Bioengineering Co.Ltd(300813) (hereinafter referred to as ” Zhejiangtailin Bioengineering Co.Ltd(300813) “, “the company” or “the issuer”) as the sponsor of its project of issuing convertible corporate bonds (hereinafter referred to as “convertible bonds”) to unspecified objects.
The recommendation institution and the designated recommendation representative have been in accordance with the company law of the people’s Republic of China (hereinafter referred to as the “company law”), the securities law of the people’s Republic of China (hereinafter referred to as the “Securities Law”) and the administrative measures for the registration of securities issuance of companies listed on the gem (for Trial Implementation) (hereinafter referred to as the “administrative measures for registration”) ）And other relevant laws and regulations and the relevant provisions of the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”), be honest, trustworthy, diligent and responsible, issue this issuance recommendation letter in strict accordance with the business rules, industry practice norms and ethical standards formulated according to law, and ensure the authenticity, accuracy, integrity and timeliness of the documents issued by the securities.
Unless otherwise specified in the issuance recommendation letter, relevant terms have the same meaning as in the prospectus for issuance of convertible corporate bonds to unspecified objects on the Zhejiangtailin Bioengineering Co.Ltd(300813) gem.
Section 1 basic information of this securities issuance
1、 Basic information of relevant personnel designated by the recommendation institution
(i) Name of sponsor
China Greatwall Securities Co.Ltd(002939) 。
（2） Be responsible for recommending the sponsor representative and practice of this securities issuance
Bai Yimin and Shi Yi are the recommendation representatives specifically responsible for the recommendation, and their practice of recommendation business is as follows:
Bai Yimin, China Greatwall Securities Co.Ltd(002939) director, deputy general manager of investment banking division and sponsor representative. Mr. Bai Yimin has successively served as senior manager and deputy director of Huatai United Securities Investment Banking Department. As the on-site principal, he has completed Boya Bio-Pharmaceutical Group Co.Ltd(300294) gem IPO project, Beihai Gofar Chuanshan Biological Co.Ltd(600538) and Jinke Property Group Co.Ltd(000656) non-public offering project, Beijing Water Business Doctor Co.Ltd(300055) , Tecon Biology Co.Ltd(002100) and Boya Bio-Pharmaceutical Group Co.Ltd(300294) and other major asset restructuring financial consulting projects, and participated in the completion of Shenzhen Capchem Technology.Ltd(300037) , Shenzhen Fenda Technology Co.Ltd(002681) , Nanfang Black Sesame Group Co.Ltd(000716) IPO or refinancing projects such as Shenzhen Topband Co.Ltd(002139) .
Shi Yi, China Greatwall Securities Co.Ltd(002939) business director of investment banking division, sponsor representative, master degree. He has successively worked in Shenzhen Branch of Deloitte Touche Tohmatsu, Huatai United Securities and Ping An Securities, participated in the audit of Linzhou heavy machinery, Zhejiang Giuseppe Garment Co.Ltd(002687) , Guangdong Yizumi Precision Machinery Co.Ltd(300415) , Oupu steel network, Vatti Corporation Limited(002035) , and participated in the completion of Qtone Education Group(Guangdong) Co.Ltd(300359) , Tecon Biology Co.Ltd(002100) , Boya Bio-Pharmaceutical Group Co.Ltd(300294) major asset restructuring projects, Jinke Property Group Co.Ltd(000656) non-public offering, Persian technology Shundian shares are listed in the national share transfer system and other projects.
（3） Co sponsors of this securities issuance project and other project team members
1. Project Co organizers
Shu Xi (resigned), with a master’s degree. As a member of the project team, Ms. Shu Xi has participated in Shenzhen Minde Electronics Technology Ltd(300656) IPO project, Shenzhen Minde Electronics Technology Ltd(300656) major asset restructuring, IPO project of Guangzhou jusailong Engineering Plastics Co., Ltd., with a good practice record.
2. Other members of the project team
Other members of the project team participating in the Zhejiangtailin Bioengineering Co.Ltd(300813) offering recommendation include Chen Lu, Yao Xinghao and Gao Jun.
2、 Basic information of the issuer
(i) Basic information of the issuer
Chinese name of the company: Zhejiangtailin Bioengineering Co.Ltd(300813)
English name of the company: Zhejiang Tailin Bioengineering Co., Ltd
Registered address: No. 2930, South Ring Road, Binjiang District, Hangzhou
Office address: No. 2930, South Ring Road, Binjiang District, Hangzhou
Legal representative: ye Dalin
Date of establishment of the joint stock company: April 30, 2015
Registered capital: 51.97 million yuan
Unified social credit Code: 91330100735254191q
Production: pore size tester, bacteria collection incubator, isolation system, Bacteria collector (except for medical use), microbial limit tester, homogenizer, barreled water sampler, endoscopic microbial detector, Raman spectrometer, disinfection equipment (gaseous hydrogen peroxide, dry fog hydrogen peroxide), total organic carbon analyzer, filter membrane integrity tester, glove integrity tester, microbial culture medium, strain and other reagent consumables, analytical instruments, class II medical devices; service: food business scope: technical development of products, drug production and testing equipment, purification equipment, analytical instruments, filtration equipment and experimental testing supplies , technical consultation, technical services, achievement transfer, exhibition services, Non certificate labor vocational skill training for adults (except for projects involving pre-approval), property management, design and installation of indoor environmental purification project and water treatment project; wholesale and retail: hardware, electrical appliances, purification equipment, analytical instruments, testing equipment, filtration equipment, plastic products and chemical products (excluding dangerous chemicals and precursor chemicals), class II medical devices, import and export of goods
Company website: http://www. tailingood. com./
Contact: 0571-86589069
Zhejiangtailin Bioengineering Co.Ltd(300813) its main business is the R & D, manufacturing and sales of pharmaceutical equipment such as microbial detection and control technology system products and organic analysis instruments. The products include all kinds of consumables, instruments and equipment, which can be used alone or in combination for the production and quality detection of sterile drugs. At the same time, the application fields that can be expanded include medical health, food safety, disease prevention and control, biosafety Major health industries such as inspection and quarantine, bioengineering, experimental animals and environmental protection.
The issuer is a market pioneer in the field of microbiological testing in China. During the reporting period when China first developed microorganisms for modern microbiological testing methods, the sales volume, quality, technical level and R & D innovation ability of the company’s incubators, sterile isolators and other products were in a leading position in China, It occupies a leading position in the field of products related to microbial detection and control technology system, and has always led and promoted the development of microbial detection and control technology and related products in China. In view of the completeness of the company’s current product series and continuous product development and technical reserves, in the foreseeable future, The company has the ability to continue to maintain and steadily improve its market position.
Testing instruments and supporting consumables, and realized large-scale production. By promoting the revision of technical and operational standards such as “1101 sterility test method” and “1105 and 1106 microbial limit test for non sterile products” in Chinese Pharmacopoeia, the company has promoted the application of modern microbial detection system in the field of sterility test for injection preparations and microbial limit test for oral and external preparations for China’s pharmaceutical industry; At the same time, focusing on the operation requirements of microbial detection and sterility inspection in the pharmaceutical industry, the company has developed China’s first VHP sterilizer, sterile isolator and sterile transfer cabin, and created the most complete microbial detection and control technology system in China’s product line. The company is also one of the earliest enterprises in China to develop TOC analyzer with thin film conductivity detection method, and promoted the revision of total organic carbon standard for pharmaceutical water in Chinese Pharmacopoeia, so that relevant products have been popularized and applied in the detection of pharmaceutical water.
（2） Type of securities issuance
Issue convertible corporate bonds to unspecified objects in Shenzhen Stock Exchange.
（3） Latest equity structure of the issuer
As of December 31, 2020, the share capital structure of the issuer is as follows:
Number of projects (10000 shares)
1、 Shares with limited sales conditions 3897.0074 99%
2、 Shares with unlimited sales conditions 1300.0025 01%
Including: RMB 1300.0025 million common shares 01%
3、 Total shares 5197.00100.00 00%
（4） Shareholding of the top ten shareholders of the issuer
As of December 31, 2020, the shareholding of the top ten shareholders of the issuer is as follows:
Shareholder name shareholder nature shareholding proportion total number of shares held (%) (shares) (shares)
Natural person in Ye Dalin 53.492780000027800000
Ningbo Gaode Equity Investment Management Co., Ltd. 7.2237500003750000
Management partnership (limited partnership)
Ni Weiju domestic natural person: 5.833030000
Pan Chunxiao domestic natural person 2.89150000150000150000
Xia xinqun natural person 1.02530100530100
Shen Zhilin domestic natural person 1.02530100530100
Tianfeng Securities Co.Ltd(601162) domestic legal person 0.96500000
Li Kaixian domestic natural person 0.5830000300000
Natural person in Guo Jinjiang 0.5830000300000
Jiangxi greedy play information technology Co., Ltd. domestic legal person 0.42219800-
（5） Statement of previous fund raising, cash dividends and changes in net assets since the issuer’s listing
The net assets at the end of the initial period (December 31, 2019) were 229.1056 million yuan
Time of issue total amount of financing by issue category (RMB 10000) previous financing ipo23855.00 in 2020
Total 23855.00
Time and amount (10000 yuan)
Accumulated cash distribution after IPO: 3118.20 yuan in 2020
1039.40 in 2021
Total 4157.60
The audited net profit at the end of the most recent year before the issuance was 44424.47
Assets (10000 yuan) (2020-12-31)
Net assets at the end of the most recent period before the issuance (RMB 4538431)
(yuan) (March 31, 2021)
Note: the 2020 dividend plan has been considered and implemented by the 2020 shareholders’ meeting.
（6） Main financial data and financial indicators of the issuer in recent three years
Tianjian Certified Public Accountants (special general partnership) audited the company’s financial reports for 2018, 2019 and 2020, and issued standard unqualified audit reports respectively.
Unless otherwise specified, the financial data and information involved in this letter of recommendation are extracted from the above financial reports audited by accountants in 2018, 2019 and 2020, and the financial data from January to September 2021 are extracted from the company
